Skip to content
    Guidelines & Consensus

    Cohort analyses validate IWG 2023 response criteria in higher-risk MDS

    Bewersdorf et alHaematologica

    Cohort analyses validate IWG 2023 response criteria in higher-risk MDS
    The International Working Group (IWG) 2023 response criteria for higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) introduced updated endpoints, including composite complete remission (cCR), but external clinical validation has remained limited. To evaluate the prognostic validity of these criteria, researchers analyzed overall survival (OS) stratified by best response according to IWG 2023 standards across two independent cohorts of HR-MDS patients receiving hypomethylating agent (HMA)–based regimens.
    The analysis included a total of 1,268 patients derived from two distinct datasets: the retrospective International Consortium for MDS (icMDS) VALIDATE database (n = 1,047) and the randomized, phase III PANTHER clinical trial cohort evaluating azacitidine in combination with pevonedistat or placebo (n = 221).
    In both the observational and prospective trial datasets, achievement of cCR under the IWG 2023 definitions was consistently associated with significantly improved overall survival compared to non-achievement of cCR across univariate and multivariable analyses. In the multivariable model within the VALIDATE dataset, cCR conferred a significant survival advantage (hazard ratio [HR]: 0.65; 95% CI: 0.55–0.76), supporting the clinical utility and prognostic relevance of the updated IWG 2023 response criteria for patients undergoing HMA-based therapy.

    Key Takeaways

    • Patients with higher-risk myelodysplastic syndromes achieving composite complete remission (cCR) per IWG 2023 criteria demonstrated superior overall survival compared to those not achieving cCR across both univariate and multivariable analyses in two independent cohorts.
    • In the multivariable analysis of the VALIDATE cohort, achievement of composite complete remission was associated with improved overall survival (HR: 0.65; 95% CI: 0.55–0.76).